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Introduction: Novel agents and the availability of autologous stem cell transplantation have revolutionized 
the treatment of patients with multiple myeloma. First generation novel agents, thalidomide, lenalidomide 
and bortezomib have significantly improved response and survival of patients. Second generation novel 
agents such as pomalidomide, carfilzomib, and monoclonal antibodies are being tested both in the newly 
diagnosed and relapse settings, and results are promising.  
Areas covered: In this review article, the main results derived from phase III trials with thalidomide, 
lenalidomide and bortezomib for the treatment of myeloma patients, both at diagnosis and at relapse, are 
summarized. Data about second generation novel agents such as pomalidomide and carfilzomib are also 
reported. Newer effective drugs currently under investigation and the promising results with monoclonal 
antibodies are described.  
Expert opinion: The availability of new effective drugs has considerably increased the treatment options for 
myeloma patients. A sequential approach including induction, transplantation (when possible), 
consolidation and maintenance is an optimal strategy to achieve disease control and prolong survival. 
Despite these improvements, the best combination, the optimal sequence and the proper target of newer 
drugs need to be defined. 
 
 
1. Introduction  
Multiple myeloma (MM) accounts for 1.6% of all cancers, 13%  of all hematologic malignancies and 1.9% of 
all cancer deaths[1]. The diagnosis of MM requires the presence of at least 10% clonal plasma cells on bone 
marrow examination and/or a biopsy-proven plasmacytoma, as well as evidence of end-organ damage 
based on CRAB criteria (ie, hypercalcemia, renal insufficiency, anemia, or bone lesions)[2]. Recently, clonal 
bone marrow plasma cell percentage of 60% or higher, involved/uninvolved serum free light chain ratio of 
100 or higher, more than one focal lesion on magnetic resonance imaging studies have been considered as 
biomarkers associated with near inevitable development of CRAB features[3].  
In the past decade, the introduction of autologous stem-cell transplantation (ASCT) and the availability of 
novel agents such as thalidomide, lenalidomide, and bortezomib have revolutionized the treatment 
paradigm of MM, with considerable improvements in responses and survival[4]. In Europe, patients <65 
years with no comorbidities are considered suitable for ASCT, while conventional chemotherapy is the 
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option in patients ≥65 years, with gentler approaches for patients over 75 years. In both young and elderly 
patients, induction therapies and maintenance strategies including novel agents are commonly adopted. 
Yet, MM patients eventually relapse or become refractory to currently available drugs. Second-generation 
novel agents and new combinations are being tested in ongoing clinical trials and will further increase the 
treatment options for MM patients.  
 
2. APPROVED NOVEL AGENTS 
2.1 Immunomodulatory drugs 
2.1.1 Thalidomide 
The combination melphalan-prednisone (MP) had long been the standard of care for patients not eligible 
for high-dose therapy and transplantation. Thalidomide, an immunomodulatory drug (IMiD), was the first 
novel agent to be approved for the treatment of MM. An efficacy meta-analysis of six trials, including 1685 
newly-diagnosed (ND) MM patients (Table 1)[5], showed that the addition of thalidomide to MP (MPT) 
significantly prolonged both progression-free survival (PFS) and overall survival (OS) compared to MP[6]. 
Based on these data, in Europe, MPT was adopted as a standard of care in transplant-ineligible patients 
until recently, when new and more effective combinations became available.  The benefit obtained with 
thalidomide has provided the basis for the development of new generation IMiDs, lenalidomide and 
pomalidomide. 
2.1.2 Lenalidomide 
Lenalidomide is a second generation IMiD currently used for the treatment of both relapse/refractory (RR) 
and NDMM patients. Based on the results of two phase III trials, MM009 and MM010, conducted in RRMM 
patients, lenalidomide plus dexamethasone demonstrated to be superior to dexamethasone alone, both in 
terms of responses and outcomes (PFS and OS)[7,8]. These results led to the approval of lenalidomide for 
RRMM patients in USA and in Europe in 2006. 
The excellent results observed in the relapse setting paved the way for the investigation of lenalidomide as 
part of the upfront treatment in ND patients. 
In a phase III trial, lenalidomide plus high-dose dexamethasone (RD) was compared to lenalidomide plus 
low-dose dexamethasone (Rd) in ND patients, both eligible and ineligible for ASCT[9]. Despite a higher 
overall response rate (ORR) with RD (79% vs. 68.3%, p=0.008), patients treated with Rd had a significantly 
longer 2-year OS (75% vs. 87%, p<0.001). The survival benefit associated with Rd was particularly evident in 
patients older than 65 years of age (1-year OS: 83% with RD vs. 94% with Rd).   
Two phase III trials in ASCT-eligible patients investigated lenalidomide administered both during 
induction/consolidation and maintenance; after induction treatment (Rd), patients were randomized to 
ASCT or conventional chemotherapy (CC). In the MPR-MEL200 trial, 402 patients were firstly randomized to 
either melphalan-lenalidomide-prednisone (MPR) or ASCT and then to lenalidomide maintenance or no 
maintenance [10]. ASCT proved to be superior to MPR both in terms of PFS (median, 43 months vs 22.4 
months; p<0.001) and 4-year OS (82% vs 65%; p=0.02). In the CRD-MEL200 trial, 389 NDMM patients could 
receive either ASCT or CC [cyclophosphamide-lenalidomide-dexamethasone (CRD)]; after a second 
randomization patients were allocated to lenalidomide maintenance alone or with prednisone (RP). ASCT 




The phase III FIRST trial compared for the first time upfront thalidomide (MPT) and lenalidomide, given 
continuously (Rd) until progression or in a fixed schedule of 18 cycles (Rd-18)[12]. In 1623 ND ASCT-
ineligible patients,  Rd significantly prolonged median PFS (25 months) as compared to both Rd-18 (21 
months; p<0.001) and MPT (21 months; p<0.001). Furthermore, Rd significantly reduced the risk of death 
by 22% as compared to MPT. The longer median PFS2 reported among patients treated with Rd in 
comparison with those who received MPT (43 months vs 36; p=0.005) showed that a prolonged 
lenalidomide exposure did not negatively affect the responsiveness to second-line treatment. This study 
demonstrated the superiority of the doublet, alkylating-free regimen Rd over MPT. 
The EMN01 trial compared a 2-drug alkylator-free regimen (Rd) versus 3-drug lenalidomide-based regimens 
[cyclophosphamide-prednisone-lenalidomide (CPR) and MPR] in 662 NDMM elderly patients[13]. All 
patients received maintenance with lenalidomide alone or with prednisone (RP). No significant differences 
in terms of median PFS (23 vs 23 vs 27 months) and 3-year OS (73% vs 72% vs 67%) were detected among 
Rd, CPR and MPR arms, respectively. A slight PFS advantage was observed in patients <75 years treated 
with MPR, while no differences were reported between 2- and 3-drug regimens among patients >75 years. 
Six phase III trials explored the role of lenalidomide as a maintenance agent. In the transplant setting, three 
studies in which lenalidomide was compared to placebo or no maintenance showed a significant PFS 
benefit in favor of lenalidomide maintenance but in only one a significant OS advantage was 
detected[10,14,15]. In the CRD-Mel200 trial, the addition of prednisone to lenalidomide showed a PFS 
benefit as compared to lenalidomide alone (2-year PFS: 83% vs 64%; p=0.02)[11]. Among 459 elderly 
patients, MPR followed by lenalidomide (MPR-R) significantly improved median PFS in comparison with 
MPR and MP (31 months vs. 14 months vs. 13 months; p<0.001). This advantage was more evident in 
patients younger than 75 years, in whom MPR-R significantly improved PFS compared to MPR and MP. In a 
landmark analysis from start of maintenance, lenalidomide maintenance significantly prolonged PFS as 
compared to placebo, regardless of age (26 months with MPR-R vs. 7 months with MPR-placebo, p<0.001), 
with a 66% reduced risk of progression. A concern about second primary malignancies (SPM) with a long-
term use of lenalidomide has been raised: a meta-analysis showed that the risk of developing an SPM was 
higher when lenalidomide was combined with alkylating agents, especially melphalan[16].  
 
2.1.3 Pomalidomide 
Pomalidomide is a third generation IMiD that demonstrated efficacy in MM patients refractory to both 
lenalidomide and bortezomib. Several phase I/II studies explored the activity of pomalidomide (2 to 4 mg), 
both alone or in combination with dexamethasone: the ORR ranged from 26% to 65% and median PFS from 
3 to 13 months, based on the number of prior therapies (median 2 to 6) and the refractoriness status to 
bortezomib and lenalidomide. The IFM 2009-002 study explored two schedules of pomalidomide-
dexamethasone: pomalidomide given for 21 days of a 28-day cycle (21/28) or  continuously during a 28-day 
cycle (28/28). No differences in responses and outcomes were reported. The investigators recommended 
the 21/28 schedule for a better marrow recovery [17]. In the phase III MM-003 trial pomalidomide-
dexamethasone (4 mg, 21/28) was compared to high-dose dexamethasone (HiDex) in 455 MM patients RR 
to both lenalidomide and bortezomib [18]. Pomalidomide-dexamethasone induced a higher ORR than 
HiDex (21% vs 3%; p<0.001) and significantly prolonged median PFS (4 months vs 2 months; p<0.001) and 
OS (not reached vs 8 months, p<0.001).  
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Pomalidomide was then approved by the FDA and the EMA  in 2013 for use alone (USA) or in combination 
with dexamethasone in patients with MM who have received at least two prior therapies including 
lenalidomide and bortezomib and have demonstrated disease progression on their last therapy[19]. 
Promising results were achieved with the combination of pomalidomide and alkylating agents or 
proteasome inhibitors (PI). Pomalidomide-cyclophosphamide-prednisone (PCP), administered to 69 RRMM 
patients in a phase Ib/II study, led to an ORR of 51% (46% in lenalidomide-refractory patients), a median 
PFS of 10 months and a 1-year OS rate of 69%[20]. The addition of cyclophosphamide to pomalidomide-
dexamethasone (PCD) was compared to pomalidomide-dexamethasone in a phase II study[21]; PCD lead to 
a higher response rate (65% vs 39%; p=0.03), and longer median PFS (9 vs 4 months; p=0.04) and OS (16 
months vs 10; p=0.08). In a phase I/II trial in RR patients, pomalidomide-dexamethasone plus bortezomib 
(PVD) showed to be well tolerated and highly effective, with an ORR of 81% and a median PFS of 17.7 
months[22]. The synergistic activity of pomalidomide and the second generation PI, Carfilzomib (KPd) is 
currently under investigation: preliminary results from an ongoing phase Ib/II study confirmed the role of 
this association, reporting an ORR of 72% (ORR 78% in PIs naïve/sensitive patients)[23].  
Pomalidomide demonstrated to be safe and effective in patients with mild to moderate renal impairment  
(clearance creatinine  > 45 ml/min). Two ongoing studies (MM-008 and MM-013) will help to determine the 
optimal dose of pomalidomide in patients with severe renal impairment (creatinine clearance <30 ml/min).  
 
2.2 Proteasome Inhibitors 
Proteasome inhibitors (PI) are a class of novel agents targeting the proteasome. Their activity is generally 
higher in neoplastic cells, thus resulting in activation of pro- and anti-proliferative signals, disruption of cell-
cycle regulation, and activation of apoptotic pathways and cell death. Bortezomib is the first in class PI 
approved by the US FDA for the treatment of NDMM and RRMM. Second-generation PIs include 
carfilzomib, already licensed by the FDA for RRMM patients, and other compounds currently under 
development such as Oprozomib, Ixazomib and Marizomib.   
2.2.1 Bortezomib 
Bortezomib is the first PI introduced into MM clinical practice; it is a boronic acid derivative that reversibly 
inhibits the chymotrypsin- and caspase-like activities of both the constitutive proteasome and the 
immunoproteasome [24,25]. Bortezomib was granted approval by the FDA and EMA for the treatment of 
MM patients who relapsed after at least 1 prior line based on the results of the phase III APEX trial, 
comparing bortezomib plus dexamethasone (VD) to dexamethasone alone. VD showed longer median time-
to-progression (TTP, 6 months vs 3 months; p<0.001) and OS (30 months vs 24 months; p<0.001) compared 
with dexamethasone.  
In NDMM patients, bortezomib is currently used in pre-transplant induction regimens, in association with 
steroids and IMIDs and/or chemotherapy, as well as in elderly, transplant-ineligible patients.  
In ASCT-eligible patients, VD induced higher response rates than vincristine-doxorubicin-prednisone (VAD), 
with a VGPR rate of 38% vs 15% after induction, which improved after transplantation (54% vs 37%). The 
difference between response rates translated into a PFS improvement in favor of VD (36 months vs. 30 
months, p=0.064)[26]. The 3-drug regimen bortezomib, thalidomide and dexamethasone (VTD) has been 
compared with the 2-drug thalidomide-dexamethasone (TD) and with VD[27,28]. In a phase III study VTD, 
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as induction and consolidation after ASCT, resulted in higher nCR/CR rates after consolidation as compared 
to TD (73% vs 61%; p=0.02), with a significant increase in the nCR/CR rate in the VTD group after 
consolidation treatment. VTD, in comparison with TD, prolonged 3-year PFS (60% vs 42%; p=0.04. Similar 
results were reported in another phase III trial comparing VTD (with a reduced-dose of bortezomib) and VD 
as induction treatment. Better quality of responses (VGPR/CR, 49% vs 36%, P = 0.05) and longer median PFS 
were reported with VD induction. Nevertheless, none of the two studies found an OS advantage in favor of 
VD[29]. The combinations of VD plus lenalidomide (VRD) or cyclophosphamide (VCD) are adopted for the 
upfront treatment of ASCT-eligible patients. Data from the phase II EVOLUTION trial showed a similar 
activity between VCD and VRD; furthermore, the addition of lenalidomide to VCD (VCRD) did not increase 
the CR rate as compared to 3-drug regimens. 
Bortezomib has demonstrated excellent results in elderly patients and has become a back-bone in the 
treatment of ASCT-ineligible patients. The randomized phase III VISTA study compared bortezomib plus MP 
(VMP) and MP in 682 ASCT-ineligible patients. VMP proved to be superior to MP inducing a higher ORR 
(71% vs 35%; p<0.001) and CR rate (30% vs 4%; p<0.001) and a longer median TTP (24 vs 17 months; 
p<0.001). An updated analysis confirmed the OS advantage with VMP in comparison with MP (3-year OS: 
68% vs 54%)[30]. A Spanish phase III trial randomized 260 patients to receive either VMP or bortezomib-
thalidomide-prednisone (VTP) as induction treatment, followed by either VP or VT maintenance. No 
differences were recorded in terms of PFS and OS between VMP and VTP. After the second randomization, 
patients who were maintained with VT had longer PFS (median, 39 vs 32 months; p=0.1) and 5-year OS 
(69% vs 59%;p =0.1). On the other hand, VT maintenance was more toxic than VP in terms of grade 3/4 
non-hematologic adverse events (17% vs 5%; p=0.009)[31]. The phase III GIMEMA trial compared standard 
VMP to the 4-drug VMP plus thalidomide (VMPT) followed by VT maintenance in 511 patients over 65 
years[32,33].  A significant PFS (median, 35 vs 25 months; p<0.001) and 5-year OS (61% VS 51%; P=0.01) 
advantage was reported with VMPT-VT as compared with VMP. This advantage was particularly evident in 
patients less than 75 years. Furthermore, when bortezomib schedule was changed from twice-weekly to 
once-weekly, the rate of grade 3/4 toxicities decreased without affecting efficacy. 
A prospective randomized study in relapsed patients compared subcutaneous vs intravenous 
bortezomib[34]. Bortezomib administered subcutaneously showed to be as effective as intravenous 
bortezomib, with the advantage of a significant reduction in peripheral neuropathy. Based on these results, 
subcutaneous bortezomib was granted approval. 
2.2.2 Carfilzomib 
Carfilzomib primarily inhibits chymotripsin-like site of the proteasome, forming a stable and irreversible 
adduct with the proteasome excretion[35,36]. Carfilzomib has been investigated in both the relapse and 
the upfront settings, either alone or in combination with steroids, alkylators and novel agents. 
The pivotal study that granted the FDA approval of carfilzomib for the treatment of RRMM is the phase II 
trial (PX-171-003-A1) that enrolled 266 patients (median of 5 prior therapies) treated with twice-weekly 
carfilzomib (20/27 mg/m2)[37]. The ORR was 24%, the median duration of response was 8 months and OS 
16 months; a similar ORR (20%) was reported among patients who were refractory or intolerant to 
bortezomib and lenalidomide. Carfilzomib was then granted accelerated approval by the FDA in 2012 for 
the treatment of patients with MM who have received at least two prior therapies, including bortezomib 
and an IMiD, and who have demonstrated disease progression on or within 60 days of completion of last 
therapy. In the PX-171-007 study, different doses of escalated carfilzomib were tested: 36, 45, 56 or 70 
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mg/m2, alone or in combination with dexamethasone[38]. At the maximum tolerated dose (MTD) of 
carfilzomib (56 mg/m2), the ORR was 50% for patients receiving carfilzomib only and 55% for those 
receiving carfilzomib-dexamethasone. In the CHAMPION-1 study, a the MTD (70 mg/m2) of once-weekly 
carfilzomib, a 93% ORR was observed in RR patients [39].  
The promising results reported in the phase Ib/II PX-171-006 trial led to the randomized, phase III ASPIRE  
trial that assessed the addition of carfilzomib (20/27 mg/m2) to Rd (KRd; Table 2)[40]. A total of 792 RR 
patients were randomized to receive either KRd or Rd. KRd induced a higher CR rate (35% vs 9%; p<0.0001) 
and  significantly prolonged median PFS (26 vs 18 months; p=0.0001) as compared to Rd; noteworthy, a 
trend toward a better 2-year OS was reported in the KRd arm (73% vs 65%; p=0.04).  
Data about the head-to head comparison between carfilzomib and bortezomib in the ENDEAVOUR study 
have been recently presented[41]. 929 RRMM patients were randomized to receive either carfilzomib or 
bortezomib ,plus dexamethasone. Patients in the carfilzomib arm had a higher rate of ORR, at least VGPR 
and CR rate, resulting into a significantly longer PFS (median, 18.7 months vs 9.4 months; HR 0.53; 
p<0.0001).  
In the upfront setting, carfilzomib has been tested in combinations with IMiDs,  alkylating agents and 
HDACIs. In the phase II CARTHADEX  trial including ASCT-eligible patients, induction with carfilzomib 
combined with thalidomide and dexamethasone resulted in a 90% ORR[42]. In a phase Ib/II trial conducted 
in 53 patients, KRd induced an ORR of 98%, with a 68% ≥nCR rate [43].  Among 58 elderly patients enrolled 
in a phase II trial, the combination of carfilzomib, cyclophosphamide and dexamethasone induced an ORR 
of 95% after induction, with a sCR rate of 20%[44].  
A formal comparison between bortezomib and carfilzomib combined with MP is currently ongoing in a 
randomized, phase III trial (CLARION). 
 
2.3 Histone deacetylase inhibitors  
2.3.1 Panobinostat 
Histone deacetylase inhibitors (HDACis) are a new class of compounds active against MM. Deacetylases are 
a group of enzymes that regulate activity of proteins post-translationally by reversing protein acetylation. 
They play a role in many cellular processes, including gene expression and protein degradation [45], 
Panobinostat is a potent inhibitor of all class I, II, and IV histone deacetylase (HDACs). The synergistic 
activity of panobinostat, bortezomib and dexamethasone (PVD) was tested in a phase Ib trial [46]. The MTD 
of panobinostat was determined at the dose of 20 mg three times a week in a 21-day cycle; the results 
from the phase II expansion cohort led to the choice of the 2 weeks on/1 week off schedule instead of the 
continuous schedule, better tolerated and more effective. Results from this trial influenced the schedule 
adopted in the phase II PANORAMA2 and the subsequent phase III PANORAMA1 trials. In the PANORAMA2 
trial, conducted in 55 RRMM bortezomib-refractory patients, PVD induced an ORR of 35%, that translated 
into median PFS and OS of 5 and 17 months, respectively [47]. The addition of panobinostat to VD 
demonstrated to be able to re-capture approximately 1/3 of bortezomib-refractory patients. Those results 
provided the rationale for the randomized, phase III PANORAMA1 trial in which 768 RRMM patients (not-
bortezomib refractory) were randomized to either PVD or VD [48]. Despite a similar ORR, the better quality 
of responses obtained with PVD (nCR/CR rate 28% vs 16%; p=0.0006) induced a longer PFS (median, 12 
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months vs 8 months; p<0.0001), while no significant survival benefit detected between the two arms 
(median, 34 vs 30 months; p=0.026). The advantage reported among patients who were treated with PVD 
was consistent despite age (<65 vs >65 years), ISS (I vs II/III) or previous treatment with bortezomib. Based 
on these data, on February 2015, the FDA approved panobinostat for use in combination with bortezomib 
and dexamethasone for the treatment of myeloma patients who received at least 2 prior regimens, 
including bortezomib and IMiDs. Combinations of panobinostat with new drugs such as carfilzomib and 
lenalidomide are currently under evaluation.  
2.3.2 Bendamustine 
Bendamustine is a peculiar bi-functional alkylator used in many lymphoproliferative disorders. It has been 
tested in both ND and RRMM patients in combination with various drugs, showing promising activity with 
currently approved novel agents. In a phase II study comparing bendamustine, at two different doses (60 vs 
100 mg/m2) plus thalidomide and low-dose dexamethasone, in 94 RRMM patients, a 46% ORR was 
reported, that translated into a median PFS of 8 months[49]. The addition of bendamustine to the second 
generation IMiD, lenalidomide, has been explored in different studies, showing an interesting potential. 
The combination of bendamustine plus Rd (6 cycles plus Rd maintenance for up to 12 cycles), administered 
to MM patients relapsing after first line treatment induced a VGPR+CR rate of 53%[50]. Promising results 
have been observed with the combination of bendamustine, bortezomib and steroids, both upfront and at 
relapse. In the first report investigating this combination in patients with a median of 4 prior therapies, an 
ORR of 85% was reported[51]. Among 75 RRMM patients, bendamustine plus VD induced a 75% ORR that 
translated into median PFS and OS of 13 and 24 months, respectively[52,53].  Based on the anti-myeloma 
activity reported in the relapse setting, bendamustine is currently under investigation also in the upfront 
setting, for the treatment of both ASCT-eligible and ineligible patients[54,55]. 
 
3 Novel agents under development 
3.1 Proteasome Inhibitors 
3.1.1 Ixazomib 
Ixazomib is an orally bioavailable inhibitor of the 20S proteasome [56]. In clinical trials, ixazomib showed 
promising activity both as a single agent and in combination with dexamethasone [57-59]. Furthermore it 
exerts anti-myeloma activity in combination with IMiDs. The synergistic activity of PIs and IMiDs provided 
the rationale for the evaluation of the combination of a fully orally available combination: ixazomib plus Rd. 
In a phase I/II study enrolling NDMM patients, the recommended phase II dose (RP2D) of ixazomib 
administered once-weekly in combination with Rd was 2.23 mg/m2 [60]; hence the choice of a fixed dose ( 
4 mg) for the phase II portion of the trial in which 50 patients were enrolled. Ixazomib-Rd proved to be 
effective, with at least a partial response (≥PR) rate of 94% and a CR rate of 19% after the first four cycles, 
with a CR rate improvement to 32% after eight cycles. Similar results were reported in a second phase I/II 
trial with ixazomib-Rd among 50 ND patients [61]. At the RP2D of ixazomib (3 mg) the ≥PR rate was 93% 
and the CR rate was 24%. More interestingly, 82% of CR patients were minimal residual disease (MRD) 
negative. Ixazomib mainly caused hematologic toxicity, in particular grade 3-4 thrombocytopenia and 
neutropenia. A very low rate of grade 3-4 peripheral neuropathy has been reported with ixazomib (≤5%).  
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Promising results from phase II studies led to the ongoing, randomized, phase III trial comparing Ixazomib-
Rd to the standard Rd. Furthermore, ixazomib is currently under investigation as a maintenance agent, both 
alone or in combination with lenalidomide.  
3.1.2 Oprozomib and Marizomib 
Preliminary efficacy of oprozomib, an irreversible orally available PI, in patients with hematologic 
malignancies has been observed. A phase Ib/II study to determine the MTD and to evaluate safety and 
tolerability of oprozomib-dexamethasone is currently ongoing. The most common grade 3 toxicities 
observed were diarrhea, anemia and nausea. Preliminary results suggest that oprozomib-dexamethasone 
may reduce gastrointestinal side effects associated with oprozomib alone [62]. 
Marizomib is a potent, orally active inhibitor of the 20S proteasome, potentially able to overcome 
Bortezomib resistance in vitro [63,64]. Early studies suggest a synergistic activity of marizomib and IMiDs 
(pomalidomide and lenalidomide).  
3.2 Monoclonal Antibodies 
Monoclonal antibodies (MoAbs) can be directed against a large variety of antigen targets expressed on 
myeloma cells or on cellular and non-cellular components of the bone marrow microenvironment, such as 
signaling molecules, cell surface receptors or proteins, plasma cell growth factors and mediators of 
adhesion and invasiveness [65].  
3.2.1 Anti-CS1 
Elotuzumab 
Elotuzumab is a fully humanized monoclonal IgG1 antibody directed against human CS1, a surface 
glycoprotein involved in MM cell adhesion to bone marrow stromal cells and in NK activity regulation [66]. 
Elotuzumab has been evaluated in combination with bortezomib and lenalidomide in two Phase I and I/II 
studies, demonstrating encouraging results in terms of responses; notably, prior exposure to novel agents 
did not affect response rate [67,68]. In a recent phase III trial (ELOQUENT-2), the addition of elotuzumab to 
the standard Rd has been tested in RR patients. Elotuzumab-Rd increased the ORR (79% vs 66%; p<0.001) 
and significantly prolonged median PFS (19 vs 15 months; p<0.001) in comparison with Rd [69].  
3.2.2 Anti-CD38 
Daratumumab 
Daratumumab is a human IgG1κ MoAb that mediates destruction of CD38- expressing malignant plasma 
cells increasing the apoptosis induced by novel agents. A phase Ib study evaluated the safety, tolerability 
and dose of daratumumab in combination with VD, VTD, VMP, and pomalidomide-dexamethasone [70]: the 
addition of daratumumab did not negatively impact on safety profile. Daratumumab was also evaluated in 
combination with Rd in a phase I/II study: toxicities were manageable and encouraging activity was 
reported, as the majority of the patients achieved PR or better [71].  
SAR650984 
SAR650984 is the second IgG monoclonal antibody that binds to a unique epitope in the human CD38 
receptor; the activity of SAR650984 was evaluated in combination with Rd in pre-treated patients; 
treatment was well tolerated and responses were rapid, increasing with prolonged treatment [72]. 
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4. Conclusion  
Sequential approaches based on novel agents are a sensible choice for the treatment of MM patients, for 
both patients eligible and ineligible for ASCT. The introduction of thalidomide, lenalidomide, and 
bortezomib has considerably changed the treatment paradigm of MM patients. Second-generation novel 
agents, such as carfilzomib and pomalidomide, are already available. Newer compounds, in particular 
monoclonal antibodies are currently under investigation. The results obtained so far are promising and 
these newer drugs will significantly enrich the treatment armamentarium for MM patients, both at 
diagnosis and relapse. 
 
5. Expert Opinion  
The introduction of novel agents has dramatically changed the outcome of MM patients. A better 
understanding of myeloma cells has brought to the identification of new targets towards the new drugs are 
directed. However, despite the great efficacy of novel agents, MM patients eventually relapse. A survival 
analysis conducted among patients relapsed after first-generation new drugs has shown poor PFS (5 
months) and OS (9 months), thus highlighting the clinical need for newer compounds able to overcome 
myeloma cells resistance to currently approved anti-myeloma agents.  
Thalidomide was the first novel agent introduced in the landscape of myeloma treatment. Today, it is 
currently adopted in NDMM patients, both ASCT-eligible and ineligible. Among younger patients, 
thalidomide can be administered in combination with bortezomib during pre-transplant induction and 
consolidation. In the elderly, MPT is a standard of care. The use of thalidomide as a maintenance agent is 
often limited by its safety profile, especially among elderly patients. Thalidomide is being replaced by the 
second-generation IMiD, lenalidomide, a more potent compound with a favorable safety profile. 
Lenalidomide is approved for both RRMM patients and, more recently, for the upfront treatment of NDMM 
patients. It has demonstrated efficacy as part of the induction treatment of ASCT-eligible patients in 
combination with bortezomib and steroids. In elderly patients, Rd administered continuously has recently 
proved to be superior to MPT. Toxicities associated with lenalidomide are mainly hematologic. Its safety 
profile and the oral administration make lenalidomide a particularly attractive compound to be used 
continuously during maintenance. In both young and elderly patients, lenalidomide maintenance 
significantly delays relapse, despite a survival advantage is yet unclear. The third-generation IMiD 
Pomalidomide has shown an excellent efficacy in heavily pre-treated patients, particularly in those RR after 
bortezomib and lenalidomide; the anti-myeloma activity of pomalidomide is enhanced by the combination 
with dexamethasone. The addition of a third drug - cyclophosphamide or PIs - seems to augment responses 
and prolong survival. The safety profile of pomalidomide is similar to that of lenalidomide: most common 
toxicities derive from myelosuppression. Furthermore, pomalidomide can be safely used in patients with 
mild to moderate renal failure.   
PIs are highly active against myeloma cells. Bortezomib is a backbone of the upfront treatment of both 
young and elderly patients. In ASCT-eligible patients, bortezomib has been successfully combined with 
IMiDs (VTD and VRD), with anthracycline (PAD) and alkylators (VCD). Bortezomib-based consolidation after 
transplantation improves depth of response obtained with ASCT. In ASCT-ineligible patients, VMP is the 
treatment of choice for fit patients; moreover, bortezomib can be safely administered to patients with 
renal failure. The major issue observed with bortezomib is the emergence of peripheral neuropathy, a 
toxicity that may lead to treatment discontinuation. Data about alternative schedule (once-weekly) and 
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route of administration (subcutaneous) have demonstrated to reduce neuropathy. Second-generation PIs 
have been recently introduced in clinical studies. Carfilzomib is an irreversible PI that has shown its ability 
to overcome bortezomib refractoriness. In addition, no significant neuropathy has been observed with 
carfilzomib. The excellent activity of carfilzomib in clinical trials granted its approval by the FDA. 
Subsequently, the role of carfilzomib started to be investigated as upfront treatment and a formal 
comparison with bortezomib in ND ASCT-ineligible patients (CMP vs VMP) is currently ongoing. Other 
second-generation PIs such as ixazomib and oprozomib are intriguing molecules, particularly because of 
their oral administration. Promising results come from MoAbs, such as elotuzumab, daratumumab and 
SAR650984. Their combination with other novel agents will clarify their role in the treatment of MM.   
The biological heterogeneity typical of MM cells and the emergent drug resistance to novel agents are a big 
challenge to physicians. Despite the great efficacy of newer drugs, relapse is almost inevitable. Therefore, 
compounds with a different mechanism of action from those of available drugs are highly needed to 
increase the efficacy of standard treatments and to overcome myeloma resistance to current therapies. 
Several molecules are currently under investigation in pre-clinical and clinical studies. Filanesib, a kinase 
spindle protein inhibitor able to cause an aberrant mitotic arrest and consequent cell death, has already 
demonstrated, its ability to act synergistically with dexamethasone and proteasome inhibitors in early 
phase trials in the relapse setting, with promising response rates. Selinexor, an oral selective inhibitor of 
nuclear export (EXPO1), is another promising compound, with a brand new target in myeloma; selinexor, 
showed synergistic activity with dexamethasone and is currently under investigation in combination with 
various backbone regimens in myeloma, such as IMiDs and PIs. Preliminary data about perifosine, a 
synthetic alkylophospholipid directed against cell membranes and able to prevent the activation of AKT 
protein, showed synergism between perifosine and dexamethasone, melphalan and bortezomib.  
In the era of novel agents, the number of active compounds against myeloma cells is rapidly rising, allowing 
physicians to tailor treatment according not only to patient’s characteristics but also to the sensibility of the 
disease to the different drugs available. In this regards, the identification of biomarkers, such as cereblon 
for IMiDs and AAG for Filanesib, able to predict tumor response to treatments, is of great interest and 
paves the way to personalized treatment. 
Despite the availability of numerous anti-myeloma drugs, many questions still remain unanswered. The 
best combination, the optimal sequence and the proper target of newer drugs, are issues to be clarified in 
the next future. 
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Article highlights box 
• Novel agents have revolutionized the treatment paradigm of patients with MM 
• Thalidomide, lenalidomide, bortezomib are currently used in standard approaches in both 
patients eligible and ineligible for transplantation 
• Novel agents are today incorporated into induction and consolidation/maintenance treatment 
strategies 
• New generation novel agents with improved efficacy and better tolerability, such as 
pomalidomide, carfilzomib, and also monoclonal antibodies, are under investigation and 
preliminary results are promising. 
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1. PHASE III TRIALS IN NDMM 










Median PFS:20,3 mo 
Median OS: 39,3 mo 
Hematologic AEs: 32% 
Infection: 13% 




Len 25 mg on days 1-21 
Dex 40 mg on days 1-4, 9-12, 






1-year OS: 87% 
Fatigue: 15% 




Len 25 mg on days 1-21 
Dex 40 mg on days 1, 8, 15, and 











Benboubker [12]  
Len 25 mg on days 1-21 
Dex 40 mg on days 1, 8, 15, and 





Median PFS: 20,7 mo 
4-year OS: 56% 
Neutropenia: 26% 
Infection: 22% 
Cardiac events: 7% 
Rd  
Magarotto [13]  
Len 25 mg on days 1-21 
Dex 40 mg on days 1, 8, 15, and 





Median PFS: 25,5 mo 
4-year OS: 59% 
Neutropenia: 28% 
Infection: 29% 
Cardiac events: 12% 
CPR  
Magarotto [13] 
Len 25 mg/day on days 1-21 
Cyclo 50 mg/day or every other 
day on days 1-21 









Median PFS: 23 mo 
3-year OS: 72% 
At least a G3- 4 hematologic 
events in <75 ys pts: 33% 
At least a G3- 4 hematologic 
events in >75 ys pts: 33% 
MPR (EMN01) 
Magarotto [13] 
Len 10 mg/day on days 1- 21  
Mel 0.18-0.13 mg/Kg for 4 days 






Median PFS: 27 mo 
At least a G3- 4 hematologic 
event in <75 ys pts: 66% 
At least a G3- 4 hematologic 
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day cycle 3-year OS: 67% events in >75 ys pts: 70% 
MPR-R  
Palumbo [16] 
Mel 0.18 mg/kg on days 1- 4 
P 2 mg/kg on days 1-4 
Len 10 mg on days 1-21;  
Len maintenance: 10 mg on 










Median PFS: 31 mo 
3-year OS: 70% 
 
Neutropenia G4: 35% 




Bor 1.3 mg/m2 on days 1, 4, 8, 
and 11 
Thal 100 mg daily for the first 
14 days and 200 mg daily 
thereafter 
Dex 40 mg on days 1, 2, 4, 5, 8, 











3-year PFS: 60% 
3-year OS: 90% 
 
 
Gastrointestinal : 2% 
Peripheral neuropathy: 0,6% 
VD  
Harousseau [26] 
Bor 1.3 mg/m2 on days 1, 4, 8, 
and 11 
Dex 40 mg on days 1-4 (all 
cycles) and on days 9-12 (cycles 








Median PFS: 36 mo 






San Miguel [30]; 
  
Mel 9 mg/m2 on days 1-4 
P 60 mg/m2 on days 1-4 
Bor 1.3 mg/m2 on days 1, 4, 8, 
11, 22, 25, 29, and 32 during 
cycles 1 to 4 and on days 1, 8, 
22, and 29 during cycles 5 to 9 











2-years PFS: 50% 








Bor 1.3 mg/m2 on days 1, 8, 15, 
22 
Mel 9 mg/m2 on days 1–4 
 P 60 mg/m2 on days  1–4 
Thal 50 mg/d for nine 35-d 
cycles 
Bor-T maintenance: Bor 1.3 
mg/m2 every 14 d; Thal 50 












3-year PFS: 56% 
3-year OS: 89% 
 
 
Neutropenia: 38 % 
Thrombocytopenia: 22 % 





Bor 1.3 mg/m² on days 1, 4, 8, 
11, 22, 25, 29, and 32 
Thal 100 mg/day 






Median PFS: 25 mo 
3-year OS: 65% 
Neutropenia: 22 % 
Thrombocytopenia: 12 % 
Peripheral neuropathy: 9% 
Cardiac events: 8% 
ORR: overall response rate; PFS: progression free survival; OS: overall survival;  AEs: adverse events. Mel: melphalan; P: prednisone; Thal: 









TABLE 2: PHASE III TRIALS IN RRMM 





San Miguel [48] 
Pomalidomide 4 mg on days 
1-21 of a 28-day cycle 
Dexamethasone 40 mg on 










Carfilzomib: 20/27 mg/m2 
on days 1,2,8,9,15 and 16 
(cycles 1-12) and 1,2,15 and 
16 (cycles 13-18) of a 28-day 
cycle 
Lenalidomide: 25 mg ond 
days 1-25 of a 28-day cycle 
Dexamethasone: 40 mg on 










NR (2-year OS: 73%) 
PAN-Vd 
San Miguel [48] 
Pan 20 mg on days 1, 3, 5, 8, 
10, 12 of a21 day cycles 
Bor 1.3 mg/m2 on days 1, 4, 
8, 11 of a21 day cycles 
Dex 20 mg on days 1, 2, 4, 5, 








Lonial [68]  
Elotuzumab: 10 mg/kg on 
days 1,8,15 and 22 (cycles 1-
2) and on days 1 and 15 (from 
cycle 3) of a 28-day cycle 
Lenalidomide: 25 mg ond 
days 1-25 of a 28-day cycle 
Dexamethasone: 40 mg on 












P: pomalidomide, d:dexamethasone, K: carfilzomib, R: lenalidomide, PAN: panobinostat, V: bortezomib, ORR: overall response rate, PFS: 
progression-free-survival, OS. Overall survival, NA: not available 
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